Down-modulation of Lymphoproliferation and Interferon-γ Production by β-glucan Derived from Saccharomyces cerevisiae

Memorias do Instituto Oswaldo Cruz

Volumn 98, Issue 8, 2003, Pages 1083-1087

  Pelizon, A C ^a   Kaneno, R ^a   Soares, A M V C ^a   Meira, D A ^a   Sartori, A ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Interferon ; Lymphoproliferation; Saccharomyces cerevisiae; glucan

Indexed keywords

BETA GLUCAN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SACCHAROMYCES CEREVISIAE; SPLEEN CELL;

ANIMALIA; SACCHAROMYCES CEREVISIAE;

EID: 1342269089     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762003000800019     Document Type: Article

References (26)

1. Abel G, Czop JK 1992. Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β. Int J Immunopharmacol 14: 1363-1373.
2. Au BT, Williams TJ, Collins PD 1994. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. J Immunol 152: 5411-5419.
3. Borosková Z, Reiterová K, Dubinsky P, Tomasovicová O, Machnicka B 1998. Inhibition of lymphoproliferative response and its restoration with a glucan immunomodulator in mice with experimental larval toxocarosis. Folia Microbiol 43: 475-476.
4. Chirigos MA, Stylos WA, Schultz RM, Fullen JR 1978. Chemical and biological adjuvants capable of potentiating tumor cell vaccine. Cancer Research 38: 1085-1091.
5. Di Luzio NR, Williams DL, McNamee RB, Edwards BF, Kitahama A 1979. Comparative tumor-inhibitory and antibacterial activity of soluble and particulate glucan. Int J Cancer 24: 773-779.
6. Duan X, Ackerly M, Vivier E, Anderson P 1994. Evidence for involvement of β-glucan-binding cell surface lectins in human natural killer cell function. Cell Immunol 157: 393-402.
7. Engstad CS, Engstad RE, Olsen JO, Osterud B 2002. The effect of soluble β-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int Immunopharmacol 2: 1585-1597.
8. Estrada A, Yun CH, Kessel AV, Li B, Hauta S, Laarveld B 1997. Immunomodulatory activities of oat β-glucan in vitro and in vivo. Microbiol Immunol 41: 991-998.
9. Hassid WZ, Joslyn MA, McCready RM 1941. The molecular constitution of an insoluble polysaccharide from yeast, Saccharomyces cerevisae. J Am Chem Soc 63: 295-298.
10. Hofer M, Pospisil M 1997. Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors' results. Int J Immunopharmac 19: 607-609.
11. Ishibashi KI, Miura NN, Adachi Y, Ogura N, Tamura H, Tanaka S, Ohno N 2002. Relationship between the physical properties of Candida albicans cell well β-glucan and activation of leukocytes in vitro. Int Immunopharmacol 2: 1109-1122.
12. Kurihara K, Shingo Y, Miura NN, Horie S, Usui Y, Adachi Y, Yadomae T, Ohno N 2003. Effect of CAWS, a mannoprotein-beta-glucan complex of Candida albicans, on leukocyte, endothelial cell, and platelet functions in vitro. Biol Pharm Bull 26: 233-240.
13. Mackin WM, Brunke-Reese D, Gu Y, Crotty C, Fisette L 1994. Enhanced microbial activities of human peripheral blood monocytes and neutrophils (PMN) after pre-treatment with PGG-glucan (Betafectin™). FASEB J 8: A216.
14. Masihi KN 2000. Immunomodulators in infectious diseases panoply of possibilites. Int J Immunopharmacol 22: 1083-1091.
15. Masihi KN, Madaj K, Hintelmann H, Gast G, Kaneko Y 1997. Down-regulation of tumor necrosis factor-α, moderate reduction of interleukin-1β, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan. Int J Immunopharmacol 19: 463-468.
16. Meira DA, Pereira, PCM, Marcondes-Machado J, Mendes RP, Barraviera B, Pellegrino JRJ, Rezkallah-Iwasso MT, Peraçoli MTS, Castilho LM, Thomazini I, Silva CL, Foss NT, Curi PR 1996. The use of glucan as immunostimulant in the treatment of paracoccidioidomycosis. Am J Trop Med Hyg 55: 496-503.
17. Nakagawa Y, Ohno N, Murai T 2003. Supression by Candida albicans β-glucan of cytokine release from activated human monocytes and from T cells in the presence of monocytes. J Infect Dis 187: 710-113.
18. Olson EJ, Stading JE, Grieco-Harper N, Hoffman AO, Limper AH 1996. Fungal β-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages. Infect Immun 64: 3548-3554.
19. Poutsiaka DD, Mengozzi M, Vannier E, Sinha B, Dinarello CA 1993. Cross-linking of the β-glucan receptor on human monocytes results in interleukin-1 production. Blood 12: 3695-3700.
20. Rios-Hernandez M, Dos-Santos NJ, Cardoso S, Bello-Garciga JL, Pedroso M 1994. Immunopharmacological studies of β-1,3-glucan. Arch Med Res 25: 179-180.
21. Sandula J, Kogan G, Kacuráková M, Machová E 1999. Microbial (1 → 3)-D-glucans, their preparation, physico-chemical characterization and immunomodulatory activity. Carbohydr Polym 38: 247-253.
22. Sandula J, Machová E, Hribalová V 1995. Mitogenic activity of particulate yeast β-(1→3)-D-glucan and its water-soluble derivatives. Int J Biol Macromol 17: 323-326.
23. Soltys J, Quinn MT 1999. Modulation of endotoxin and enterotoxin-induced cytokine release by in vivo treatment with β-(1, 6)-branched β-(1, 3)-glucan. Infect Immun 67: 244-252.
24. Tzianabos AO 2000. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 13: 523-533.
25. Vassallo R, Kottom TJ, Standing JE, Limper AH 2001. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 25: 203-211
26. Vetvicka V, Thornton BP, Ross GD 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98: 50-61.